Markets don't like uncertainty. It's a fact. That's why the axiom exists. An assumed Trump win carries a certain degree of uncertainty regarding how far his enemies will go to destroy anything he tries to do. You yourself just wrote what your "source" told you. "Violence will ensue." That's exactly one of the reasons I wrote what I wrote. You're trying to draw me into a political argument, and I'm not going there. You debate like a child. I told you what's going to happen near term market-wise if the odds of a Trump win continue to increase. If Michelle decides to run, or another strong Dem emerges, then we'll reassess.
CAVA up 100%<----- Did we nail that IPO or what! Nobody was talking IPO's at the time... Tyra Biosciences 'rapidly becoming' top second half pick at Opco » 12:14 TYRA Company Profile Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. TYRA Tyra Biosciences, Inc. $16.98
Longshot: STSS Sharps Technology, Inc. $0.31 0.07(+29.41%)1:09 PM 07/03/24 NASDAQ |$USD |Realtime Chart can get us to .38 and if we are lucky .50